In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial
- 31 August 1994
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 19 (4) , 235-243
- https://doi.org/10.1016/0732-8893(94)90037-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- New quinolones in developmentExpert Opinion on Investigational Drugs, 1994
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- Sparfloxacin and other new fluoroquinolonesJournal of Antimicrobial Chemotherapy, 1992
- Infectious Complications with Respiratory Pathogens despite Ciprofloxacin TherapyNew England Journal of Medicine, 1991
- Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Use of in vitro topoisomerase II assays for studying quinolone antibacterial agentsAntimicrobial Agents and Chemotherapy, 1989
- In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agentsAntimicrobial Agents and Chemotherapy, 1989
- CIPROFLOXACIN RESISTANCE IN EPIDEMIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUSThe Lancet, 1988
- Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDaEuropean Journal of Biochemistry, 1986